Pharmacotherapy of Alcohol Use Disorders: Seventy-Five Years of Progress
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Modern pharmacotherapy for alcohol dependence has its roots in the failure of National Prohibition in the United States and the rise of the disease model of alcoholism (embodied in Alcoholics Anonymous). In 1948, disulfiram was the first medication approved by the U.S. Food and Drug Administration (FDA) to treat alcohol dependence, but its efficacy has not been supported by randomized controlled trials. In the 1960s, benzodiazepines replaced older treatments for alcohol withdrawal, but sedative and dependence-producing effects limit their utility in the postwithdrawal period. In the 1980s, the focus shifted to the treatment of co-occurring psychiatric disorders and medications that modify negative mood states, which contribute to relapse to heavy drinking. In the 1990s, developments in neurobiology implicated specific neurotransmitter systems underlying alcohol's effects, culminating in the 1994 approval by the FDA of the opioid antagonist naltrexone to treat alcohol dependence. In 2006, the FDA approved a long-acting formulation of naltrexone. Recently, nalmefene, another opioid receptor antagonist, was approved in Europe for as-needed use to reduce heavy drinking. Acamprosate, an amino acid derivative, first approved in France in 1989, received FDA approval in 2004. However, the beneficial effects of the approved medications are only modestly greater than those of placebo, and their use is limited. Topiramate, currently under investigation for alcohol dependence, has greater efficacy but a variety of adverse effects. In addition to the identification of novel compounds, the future of alcohol dependence pharmacotherapy will depend on developments in pharmacogenetics, in which genetic variation that moderates treatment efficacy and adverse effects is used to personalize treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571 · cited 2×
“In some naltrexone studies, for example, carriers of a variant (118G or Asp40) allele in OPRM1, the gene encoding the μ-opioid receptor, had a better clinical response to naltrexone than 118A (or Asn40) allele homozygotes (Anton et al., 2008; Oslin et al. 2003).”
BackgroundSelf-citationTopiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451 · cited 2×
“In some naltrexone studies, for example, carriers of a variant (118G or Asp40) allele in OPRM1, the gene encoding the μ-opioid receptor, had a better clinical response to naltrexone than 118A (or Asn40) allele homozygotes (Anton et al., 2008; Oslin et al. 2003).”
BackgroundChanges in depression among abstinent alcoholics
Brown, S. A., & Schuckit, M. A. (1988) · Journal of Studies on Alcohol · doi:10.15288/jsa.1988.49.412 · Cited by 412 · cited 4×
“(1987) later reported that, although depressive symptoms commonly occur during withdrawal, they often improve spontaneously with abstinence from alcohol, which was supported by the fi ndings of Brown and Schuckit (1988). Subsequently, there were many studies of antidepressants (both tricyclic antidepressants and selec…”
BackgroundInfluentialBuspirone Treatment of Anxious Alcoholics: A Placebo-Controlled Trial
Kranzler, H. R. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950090052008 · Cited by 248 · cited 1×
“Kranzler et al. (1994) found that buspirone was more effective than placebo in retaining anxious alcoholics in treatment, delaying relapse to heavy drinking, and, during a 6-month posttreatment follow-up period, reducing the number of drinking days.”
BackgroundSelf-citationBlednov, Y. A., & Adron Harris, R. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008584 · Cited by 123 · cited 1×
“Acamprosate appears to exert its effects through a weak antagonism of N-methyl-D-aspartate (NMDA) receptor activity and inhibition of the metabotropic glutamate receptor 5 (Blednov and Harris, 2008; Mann et al., 2008).”
Background(1967) · doi:10.15288/qjsa.1967.28.295 · Cited by 32
THE USE OF PSYCHOACTIVE DRUGS IN THE LONG‐TERM TREATMENT OF CHRONIC ALCOHOLICS
Kissin, B. (1975) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1975.tb19185.x · Cited by 28 · cited 1×
“In early studies (reviewed by Kissin, 1975), chlordiazepoxide was effi cacious in the long-term outpatient maintenance of alcoholics.”
Background
Cited by
Grant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0584 · Cited by 2,556
Grant, B. F., Chou, S. P., Saha, T. D., Pickering, R. P., Kerridge, B. T., Ruan, W. J., Huang, B., Jung, J., Zhang, H., Fan, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2161 · Cited by 1,362
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?
Mann, K., Aubin, H.-J., & Witkiewitz, K. (2017) · European Addiction Research · doi:10.1159/000481348 · Cited by 93
Treatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
Metadata
- Authors
- Zindel, L. R., & Kranzler, H. R.
- Venue
- Journal of Studies on Alcohol and Drugs, Supplement
- Publisher
- Alcohol Research Documentation, Inc.
- Published
- 2014-03
- Volume
- 75
- Issue
- supplement17
- Pages
- 79-88
- ISSN
- 1946-584X (ISSN-L)
- 1946-5858
- OpenAlex
- W2104284600
- Cited by
- 128
- References
- 11
- FWCI
- 11.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.